Annals Consult Guys - Preventing Recurrent Venous Thromboembolism in a Patient With Cancer
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2019)

Web Exclusives16 April 2019Annals Consult Guys - Preventing Recurrent Venous Thromboembolism in a Patient With CancerFREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this author and Howard H. Weitz, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W18-0043 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Annals Consult Guys brings a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations. They address medically relevant topics—whether they be poignant, thought-provoking, or just plain entertaining.For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment John Lucich, MD, FACPMarian University College of Osteopathic Medicine27 September 2021 Ignore CIs at Your Own Risk? Gentlemen, I thoroughly enjoy your broadcasts as the Consult Guys, but I have a concern about some of the information shared in this particular broadcast. One of the slides you presented summarized information from the AMPLIFY trial in which you highlighted one part that indicated that in those with active cancer, Apixaban was superior to Enoxaparin / Warfarin in terms of both Recurrent VTE / VTE-Related Death (3.7% vs 6.4%) and Major Bleeding (2.3% vs 5.0%). However, the range of the 95% Confidence Intervals for the Relative Risk (RR) for both Recurrent VTE / VTE-Related Death and Major Bleeding included the “neutral value” of 1. This essentially means that this trial failed to identify a statistically significant difference between the effectiveness or safety of these drugs for the indications / safety profiles indicated. As such, the best way to describe the results is merely to say that given the results from this trial, Apixaban looks to be the better choice, but we really don’t know for sure. Annals Consult GuysJefferson University23 November 2021 Author's Response I found the slide and yes the AMPLFIY Trial shows that “apixaban looks to be the better choice than Enoxaparin/Warfarin but we do not know for sure”. Agree with Dr. John Lucich’s assessment. Thank you for your great pick up. Author, Article, and Disclosure InformationAffiliations: Thomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Catharine B. Stack, PhD, MS, Deputy Editor, Statistics, reports that she has stock holdings in Pfizer, Johnson & Johnson, and Colgate-Palmolive. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 April 2019Volume 170, Issue 8Page: CG1KeywordsCancer preventionDiagnostic techniquesDisclosureResearch grantsResearch reporting guidelinesVenous thromboembolism ePublished: 16 April 2019 Issue Published: 16 April 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...